Precision medicine is an approach that tailors medical treatments to the individual characteristics of each patient, such as their genes, environment, and lifestyle. Precision medicine has the potential to improve patient outcomes, reduce side effects, and lower costs. However, precision medicine faces many challenges, such as the lack of reliable biomarkers that can measure the effectiveness of therapies.

Biomarkers are measurable indicators of biological processes or conditions, such as blood pressure, cholesterol levels, or tumor size. Biomarkers can help diagnose diseases, monitor disease progression, predict outcomes, and evaluate treatment response. However, not all biomarkers are equally useful. Some biomarkers are invasive, expensive, or inaccurate. Some biomarkers are not sensitive or specific enough to capture the complexity and heterogeneity of diseases. Some biomarkers are not available or accessible for all patients.

This is where Altis Labs comes in. Altis Labs is the AI-powered computational imaging company advancing precision medicine. Altis Labs believes that medical imaging, making up 90% of all healthcare data, is the richest source of clinical insight but is vastly underutilized. Medical imaging, such as CT scans, MRI scans, or PET scans, can provide non-invasive, high-resolution, and multi-dimensional information about the anatomy and function of organs and tissues. Medical imaging can also reveal subtle changes and patterns that are invisible to the human eye.

Altis Labs uses deep learning models to analyze medical imaging data and extract imaging biomarkers that can predict outcomes and quantify treatment effect more accurately. Altis Labs trains its models on the world’s largest cancer imaging database, which contains millions of images from thousands of patients across hundreds of clinical trials. Altis Labs’ models can learn from the rich and diverse data and generalize to new and unseen cases.

Altis Labs’ AI-powered imaging biomarker platform, Nota, helps leading biopharmaceutical companies to analyze clinical trial imaging data in a more meaningful way. Nota allows them to accelerate and de-risk all stages of clinical development, from preclinical to post-marketing. Nota enables them to:

  • Discover new imaging biomarkers that can stratify patients, identify responders, and optimize dosing.
  • Validate existing imaging biomarkers that can support regulatory approval and market access.
  • Monitor imaging biomarkers that can track disease progression and treatment response.
  • Compare imaging biomarkers that can benchmark against competitors and standard of care.

Altis Labs’ mission is to improve patient outcomes by using AI to advance precision medicine with imaging biomarkers. Altis Labs’ values guide them on their mission to accelerate the development of life-changing therapies. They are:

  • Patient-centric: They put patients first and strive to make a positive impact on their lives.
  • Science-driven: They use rigorous methods and cutting-edge technologies to generate robust and reproducible results.
  • Collaborative: They work together as a team and partner with leading experts and organizations in the field.
  • Innovative: They embrace challenges and opportunities and seek to create novel and impactful solutions.
  • Ethical: They uphold the highest standards of integrity, quality, and safety in everything they do.

If you are interested in learning more about Altis Labs and its AI-powered imaging biomarker platform, you can visit their website.

Also Read: How Golden Is Building A Knowledge Graph For Artificial Intelligence